S. V. Gatsura
S. V. Gatsura has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir G. Deriushkin
Federal Scientific and Clinical Center of Intensive Care and Rehabilitation
4 shared publications - A. N. Golosova
Russian University of Medicine
3 shared publications - E. A. Ulyanova
Russian University of Medicine
2 shared publications - O.A. Gatsura2 shared publications
A. P. Ternavskii
City polyclinic No. 175 of the Moscow Health Department
1 shared publication- Elena Yu. Shupenina
Russian University of Medicine
1 shared publication
Latest Publications
- 9 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (8)
A case of asymptomatic hypertrophic cardiomyopathy in outpatient practice
Hypertrophic cardiomyopathy (HCM) in asymptomatic patients is often identified on resting electrocardiography (ECG), with diagnosis confirmed by echocardiography (EchoCG) and magnetic resonance imaging (MRI). Objective. To present a clinical case of an asymptomatic, non-obstructive form of hypertrophic cardiomyopathy characterized by the predominant localization of left ventricular hypertrophy affecting the basal anteroseptal and anterior segments of the left ventricle. A clinical case description. We report a case involving a 32-year-old asymptomatic patient, S., who was monitored after changes in the resting ECG were detected during a routine medical examination. The patient underwent Holter ECG monitoring, echocardiography with the Valsalva maneuver, bicycle ergometry, and measurement of N-terminal brain natriuretic propeptide (NT-proBNP) levels as part of an outpatient assessment. Contrast-enhanced cardiac MRI was subsequently performed at the A.N. Bakulev National Medical Research Center of Cardiovascular Surgery. ECG and echocardiographic evaluations in the patient’s parents did not reveal left ventricular (LV) anomalies or hypertrophy (LVH). Genetic testing was recommended for the patient and their relatives to identify potential mutations in genes encoding sarcomeric proteins. The findings underscore that in young, asymptomatic patients with significant alterations in the ventricular complex on the resting ECG, attention must be directed to voltage criteria for LVH, using multiple ECG parameters to achieve an accurate diagnosis. Recognition of ECG signs consistent with HCM facilitates a targeted assessment of cardiac chamber structure to detect echocardiographic markers of HCM. The use of contrast-enhanced cardiac MRI is advisable to clarify echocardiographic results, evaluate the extent of myocardial fibrosis, and rule out phenocopies of HCM. Moreover, the need for genetic testing of the patient and relatives for genes with a well-established causal association with HCM is underscored. Annual follow-up for asymptomatic patients, including an evaluation of sudden cardiac death risk, is deemed essential. Conclusions. The presented case illustrates the feasibility of detecting hypertrophic cardiomyopathy in asymptomatic young patients within an outpatient setting. An annual, comprehensive diagnostic evaluation is critical for identifying both early signs of heart failure and the progression of left ventricular outflow tract obstruction.
- 9 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (8)
A case of asymptomatic hypertrophic cardiomyopathy in outpatient practice
Hypertrophic cardiomyopathy (HCM) in asymptomatic patients is often identified on resting electrocardiography (ECG), with diagnosis confirmed by echocardiography (EchoCG) and magnetic resonance imaging (MRI). Objective. To present a clinical case of an asymptomatic, non-obstructive form of hypertrophic cardiomyopathy characterized by the predominant localization of left ventricular hypertrophy affecting the basal anteroseptal and anterior segments of the left ventricle. A clinical case description. We report a case involving a 32-year-old asymptomatic patient, S., who was monitored after changes in the resting ECG were detected during a routine medical examination. The patient underwent Holter ECG monitoring, echocardiography with the Valsalva maneuver, bicycle ergometry, and measurement of N-terminal brain natriuretic propeptide (NT-proBNP) levels as part of an outpatient assessment. Contrast-enhanced cardiac MRI was subsequently performed at the A.N. Bakulev National Medical Research Center of Cardiovascular Surgery. ECG and echocardiographic evaluations in the patient’s parents did not reveal left ventricular (LV) anomalies or hypertrophy (LVH). Genetic testing was recommended for the patient and their relatives to identify potential mutations in genes encoding sarcomeric proteins. The findings underscore that in young, asymptomatic patients with significant alterations in the ventricular complex on the resting ECG, attention must be directed to voltage criteria for LVH, using multiple ECG parameters to achieve an accurate diagnosis. Recognition of ECG signs consistent with HCM facilitates a targeted assessment of cardiac chamber structure to detect echocardiographic markers of HCM. The use of contrast-enhanced cardiac MRI is advisable to clarify echocardiographic results, evaluate the extent of myocardial fibrosis, and rule out phenocopies of HCM. Moreover, the need for genetic testing of the patient and relatives for genes with a well-established causal association with HCM is underscored. Annual follow-up for asymptomatic patients, including an evaluation of sudden cardiac death risk, is deemed essential. Conclusions. The presented case illustrates the feasibility of detecting hypertrophic cardiomyopathy in asymptomatic young patients within an outpatient setting. An annual, comprehensive diagnostic evaluation is critical for identifying both early signs of heart failure and the progression of left ventricular outflow tract obstruction.
- 1 January 2022
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 13 (3)
TESTING OF RESIDENTS AS A TOOL FOR ASSESSING QUALITY OF THEIR TRAINING IN THE DISCIPLINE OF PUBLIC HEALTH AND HEALTH CARE
ТЕСТИРОВАНИЕ ОРДИНАТОРОВ КАК ИНСТРУМЕНТ ОЦЕНКИ ИХ ПОДГОТОВКИ ПО ДИСЦИПЛИНЕ
- 1 January 2022
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 13 (3)
TESTING OF RESIDENTS AS A TOOL FOR ASSESSING QUALITY OF THEIR TRAINING IN THE DISCIPLINE OF PUBLIC HEALTH AND HEALTH CARE
ТЕСТИРОВАНИЕ ОРДИНАТОРОВ КАК ИНСТРУМЕНТ ОЦЕНКИ ИХ ПОДГОТОВКИ ПО ДИСЦИПЛИНЕ
- 1 January 2022
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 13 (2)
MEDICAL GRADUATE ABOUT DISTANCE LEARNING: READINESS FOR A NEW EDUCATIONAL FORMAT
- 1 January 2022
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 13 (2)
MEDICAL GRADUATE ABOUT DISTANCE LEARNING: READINESS FOR A NEW EDUCATIONAL FORMAT
- Open Access
- 24 April 2021
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- Vol. 20 (1) , 16-23
Pharmacoeconomic analysis of the choice of antimicrobial drugs for the treatment of community-acquired pneumonia by physicians and final year medical students
The authors of the article conduct a pharmacoeconomic analysis of antimicrobial agents (AMA) prescriptions based on a survey of graduates of the medical faculty of a medical university and outpatient healthcare practitioners in Moscow. In addition to the pharmacoepidemiological part, the article also contains a pharmacoeconomic aspect to obtain a more complete picture, reflecting the choice of drugs not only in primary healthcare, but also among graduates of the medical faculty, who can potentially become its members without preliminary training in medical residency.The purpose of this study is to conduct a comparative pharmacoeconomic analysis of the AMA choice in the treatment of community-acquired pneumonia based on the data of a survey of general practitioners, district physicians and graduates of the medical faculty.Methodology. The 206 physicians took part in the anonymous voluntary survey.Results. 177 (85.9 %) of surveyed doctors were women and 62 (14.1 %) were men who made up Group 1. The average age of the surveyed doctors was 47.8±13.3 years, the average medical experience was 21.4±13.4 years. Group 2 consisted of 240 students, of which 178 were women (74.17 %) and 62 were men (25.83 %). The average age of the respondents in the group 2 was 24.8±3.3 years. When calculating the average cost of a treatment course of community-acquired pneumonia, depending on the structure of prescriptions, the value in Group 1 amounted to 420.82 rubles and 367.44 rubles in Group 2, while the share of costs for aminopenicillin drugs directly recommended for prescription to treat community-acquired pneumonia amounted to 8.35 and 4.97 %, respectively. Despite the current recommendations, respondents prefer to choose second-line AMAs, which are more expensive drugs. Respondents in both groups underestimate the first-line drugs that meet the current recommendations, namely aminopenicillins. Despite their low cost and ease of use in an outpatient setting, the frequency of their prescription remains low. The authors believe that more attention should be paid to the problem of rational use of antimicrobial agents. This problem can be solved through educational interventions at all levels of education, which can change the picture of drugs prescriptions in future, will allow practitioners and graduates of medical faculties to refer more often to clinical guidelines and patient treatment protocols. Comprehensive measures in this direction can not only positively affect the quality of medical care, but also reduce antibiotic resistance in the outpatient setting.
- 24 April 2021
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- Vol. 20 (1) , 16-23
Open AccessPharmacoeconomic analysis of the choice of antimicrobial drugs for the treatment of community-acquired pneumonia by physicians and final year medical students
The authors of the article conduct a pharmacoeconomic analysis of antimicrobial agents (AMA) prescriptions based on a survey of graduates of the medical faculty of a medical university and outpatient healthcare practitioners in Moscow. In addition to the pharmacoepidemiological part, the article also contains a pharmacoeconomic aspect to obtain a more complete picture, reflecting the choice of drugs not only in primary healthcare, but also among graduates of the medical faculty, who can potentially become its members without preliminary training in medical residency.The purpose of this study is to conduct a comparative pharmacoeconomic analysis of the AMA choice in the treatment of community-acquired pneumonia based on the data of a survey of general practitioners, district physicians and graduates of the medical faculty.Methodology. The 206 physicians took part in the anonymous voluntary survey.Results. 177 (85.9 %) of surveyed doctors were women and 62 (14.1 %) were men who made up Group 1. The average age of the surveyed doctors was 47.8±13.3 years, the average medical experience was 21.4±13.4 years. Group 2 consisted of 240 students, of which 178 were women (74.17 %) and 62 were men (25.83 %). The average age of the respondents in the group 2 was 24.8±3.3 years. When calculating the average cost of a treatment course of community-acquired pneumonia, depending on the structure of prescriptions, the value in Group 1 amounted to 420.82 rubles and 367.44 rubles in Group 2, while the share of costs for aminopenicillin drugs directly recommended for prescription to treat community-acquired pneumonia amounted to 8.35 and 4.97 %, respectively. Despite the current recommendations, respondents prefer to choose second-line AMAs, which are more expensive drugs. Respondents in both groups underestimate the first-line drugs that meet the current recommendations, namely aminopenicillins. Despite their low cost and ease of use in an outpatient setting, the frequency of their prescription remains low. The authors believe that more attention should be paid to the problem of rational use of antimicrobial agents. This problem can be solved through educational interventions at all levels of education, which can change the picture of drugs prescriptions in future, will allow practitioners and graduates of medical faculties to refer more often to clinical guidelines and patient treatment protocols. Comprehensive measures in this direction can not only positively affect the quality of medical care, but also reduce antibiotic resistance in the outpatient setting.
- Open Access
- 7 February 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (4) , 329-336
Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
- 7 February 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (4) , 329-336
Open AccessPharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
- Open Access
- 15 August 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (7) , 3809
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
Особенности выбора двойной антитромбоцитарной терапии у больных острым коронарным синдромом после чрескожного коронарного вмешательства
- 15 August 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (7) , 3809
Open AccessChoice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
Особенности выбора двойной антитромбоцитарной терапии у больных острым коронарным синдромом после чрескожного коронарного вмешательства